Comparable stake leader
Laurence W. Lytton
SEC ownership of IN8BIO, INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001740279.
Disclosed value leader
Alyeska Investment Group, L.P.
Comparable rows
25/37
Latest evidence
27 May 2026
- Public ticker
- INAB on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Laurence W. Lytton
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
25 of 37
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Laurence W. Lytton
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
27 May 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001740279
- Issuer location
- New York, NY
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of IN8BIO, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Laurence W. Lytton
Disclosed value leader
Alyeska Investment Group,...
Comparable rows
25/37
Latest evidence
27 May 2026
13D/G
13F
3/4/5
Lead comparable stake: 10%
12 rows are not safely comparable across share classes.
13D/G row: Laurence W. Lytton
Showing 1-8 of 37 holder rows.
Quick read
Laurence W. Lytton leads the comparable SEC ownership view at 10%.
25 of 37 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Laurence W. Lytton's linked filing trail.
Comparable ownership
Top 5
Laurence W. Lytton
10%
Alyeska Investment Group, L.P.
9.9%
Stonepine Capital Management, LLC
9.9%
FRANKLIN RESOURCES INC
9.4%
683 Capital Management, LLC
7.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 37 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Laurence W. Lytton |
13D/G
LYTTON LAURENCE W
|
10%
|
$1,928,701
984,031 shares
|
$0 | 22 Dec 2025 |
| Alyeska Investment Group, L.P. |
13D/G
13F
Company
|
9.9%
|
$2,097,047
966,381 shares
|
$0 | 31 Dec 2025 |
| Stonepine Capital Management, LLC |
13D/G
13F
Company
|
9.9%
|
$1,975,660
1,007,990 shares
|
$0 | 19 Dec 2025 |
| FRANKLIN RESOURCES INC |
13D/G
13F
Company
|
9.4%
|
$2,039,404
914,531 shares
|
$0 | 31 Dec 2025 |
| 683 Capital Management, LLC |
13D/G
13F
Company
|
7.9%
|
$1,510,072
770,445 shares
|
$0 | 22 Dec 2025 |
| Orin Hirschman |
13D/G
|
4.4%
|
$17,987
149,895 shares
|
-$725,036 | 30 Jun 2025 |
| BIOS Fund II, LP |
13D/G
BIOS Capital Management, LP
|
4%
|
$849,245
391,357 shares
|
-$18,941,314 | 22 Dec 2025 |
| William Tai-Wei Ho |
13D/G
3/4/5
CEO, Director
|
3.7%
|
$349,325
151,223 shares
|
$0 | 30 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 07 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-17 of 17 reporting-owner rows connected to IN8BIO, INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
17
Largest Forms 3/4/5 holder
Leslie W. Kreis
Net 12M change
$0
Latest report
27 May 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Leslie W. Kreis | 10%+ Owner | $1,289,996 | Mixed | 02 May 2025 | ||
| Aaron G.l. Fletcher | 10%+ Owner | $1,289,996 | Mixed | 02 May 2025 | ||
| William Tai-Wei Ho | CEO, Director | $189,468 | Mixed | 09 May 2026 | ||
| Peter C. Brandt | Director | $138,226 | Mixed | 09 May 2026 | ||
| Alan S. Roemer | Director | $68,329 | Mixed | 22 Dec 2025 | ||
| Patrick McCall | Chief Financial Officer | $13,085 | Mixed | 09 May 2026 | ||
| Kate Rochlin | President and COO | $12,537 | Mixed | 09 May 2026 | ||
| Trishna Goswami | Chief Medical Officer | $6,931 | Mixed | 04 Sep 2024 | ||
| Emily Fairbairn | Director | $0 | Mixed | 27 May 2026 | ||
| Corinne Epperly | Director | Mixed | 09 May 2026 | |||
| Travis Whitfill | Director | Mixed | 19 Dec 2024 | |||
| Jeremy R. Graff | Director | Mixed | 09 May 2026 | |||
| Lawrence Lamb | EVP and CSO | Mixed | 09 May 2026 | |||
| Bios Equity Partners, LP | 10%+ Owner | Mixed | 13 Aug 2021 | |||
| Luba Greenwood | Director | Mixed | 09 May 2026 | |||
| Melissa Beelen | VP, Clinical Operation | Mixed | 29 Jul 2021 | |||
| Bios Clinical Opportunity Fund, LP | 10%+ Owner | Mixed | 13 Dec 2023 |
Recent insider transactions for IN8BIO, INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Emily Fairbairn | INAB | Common Stock | Gift | -100% | -724,637 | 0 | 27 May 2026 | See footnote | ||
| William Tai-Wei Ho | INAB | Employee Stock Option (right to buy) | Award | 154,500 | 154,500 | 09 May 2026 | Direct | |||
| Luba Greenwood | INAB | Stock Option (right to buy) | Award | 22,000 | 22,000 | 09 May 2026 | Direct | |||
| Lawrence Lamb | INAB | Employee Stock Option (right to buy) | Award | 54,000 | 54,000 | 09 May 2026 | Direct | |||
| Emily Fairbairn | INAB | Stock Option (right to buy) | Award | 22,000 | 22,000 | 09 May 2026 | Direct | |||
| Patrick McCall | INAB | Employee Stock Option (right to buy) | Award | 56,250 | 56,250 | 09 May 2026 | Direct | |||
| Kate Rochlin | INAB | Employee Stock Option (right to buy) | Award | 60,000 | 60,000 | 09 May 2026 | Direct | |||
| Corinne Epperly | INAB | Stock Option (right to buy) | Award | 22,000 | 22,000 | 09 May 2026 | Direct | |||
| Peter C. Brandt | INAB | Stock Option (right to buy) | Award | 22,000 | 22,000 | 09 May 2026 | Direct | |||
| Jeremy R. Graff | INAB | Stock Option (right to buy) | Award | 22,000 | 22,000 | 09 May 2026 | Direct | |||
| Lawrence Lamb | INAB | Employee Stock Option (right to buy) | Award | 72,000 | 72,000 | 04 Feb 2026 | Direct | |||
| Patrick McCall | INAB | Employee Stock Option (right to buy) | Award | 75,000 | 75,000 | 04 Feb 2026 | Direct | |||
| Kate Rochlin | INAB | Employee Stock Option (right to buy) | Award | 80,000 | 80,000 | 04 Feb 2026 | Direct | |||
| William Tai-Wei Ho | INAB | Employee Stock Option (right to buy) | Award | 206,000 | 206,000 | 04 Feb 2026 | Direct | |||
| Kate Rochlin | INAB | Common Stock | Award | 394.3% | 7,247 | 9,085 | 22 Dec 2025 | Direct | ||
| Patrick McCall | INAB | Common Stock | Award | 324.2% | 7,247 | 9,482 | 22 Dec 2025 | Direct | ||
| William Tai-Wei Ho | INAB | Common Stock | Award | 42.7% | 36,232 | 121,168 | 22 Dec 2025 | Direct | ||
| Alan S. Roemer | INAB | Common Stock | Award | 272.8% | 36,232 | 49,514 | 22 Dec 2025 | Direct | ||
| Peter C. Brandt | INAB | Common Stock | Award | 319% | 72,464 | 95,181 | 22 Dec 2025 | Direct | ||
| Emily Fairbairn | INAB | Common Stock | Award | 724,637 | 724,637 | 22 Dec 2025 | See footnote |
* marks a reported price that did not pass the local price check.